Sector News

Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine

May 11, 2024
Life sciences

Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.

Starting in 2025, the drugmaker will co-commercialise the vaccine worldwide, except for in countries such as India, South Korea, and Japan where Novavax already has existing partnerships in place. As per the “co-exclusive” agreement, Sanofi will also support certain R&D, regulatory, and commercial expenses.

The American vaccine company has faced tough times in the post-Covid-19 landscape, going as far as to issue a “going concern” warning in 2023 about its ability to continue operating. At the time, Novavax said it was subject to “significant uncertainty” concerning future sales and funding from the US Government.

Following the deal with Sanofi, the removal of this warning was noted in Novavax’s first quarter 2024 financial results and operational highlights released today.

Novavax CEO John Jacobs told CNBC that the agreement with Sanofi would allow it to lift the “going concern” warning it first issued last year over doubts surrounding its ability to continue operations.

While Novavax’s adjuvanted Nuvaxovid (NVX-CoV2373) vaccine is not currently approved or licensed by the US Food and Drug Administration (FDA), it has been authorised by the agency under an emergency use authorisation (EUA) to prevent Covid-19 for use in individuals aged 12 and above. The EUA was amended late last year to incorporate the 2023-2024 version.

Last year, Novavax received a full marketing authorisation from the European Medicines Agency (EMA) for Nuvaxovid. The vaccine has been authorised in more than 40 markets worldwide.

The deal also gives Sanofi a sole licence to use the vaccine in combination with its flu vaccines, and non-exclusive licences to use it in combination with non-flu vaccines and Novavax’s Matrix-M adjuvant in vaccine products.

The Matrix-M adjuvant comprises naturally occurring compounds found in the bark of the soap bark tree, which is commonly found in Chile. According to Novavax, the combination of ingredients has been shown to enhance the immune system response to its vaccines.

Jean-Francois Toussaint, global head of vaccines R&D at Sanofi, commented: “With flu and Covid-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-Covid-19 combination vaccines offering patients both enhanced convenience and protection against two serious respiratory viruses.”

Jacobs added: “Novavax is now in a stronger position to refocus our efforts on leveraging our technology platform and novel adjuvant in research and development and pipeline expansion to help advance our mission of developing life-saving vaccines to fight infectious diseases.”

According to GlobalData analysts, Sanofi was the tenth top pharmaceutical company by R&D spend in 2023. The company’s R&D expenditure totalled $7.18bn, making its R&D budget 15.6% of its revenue.

GlobalData is the parent company of Pharmaceutical Technology.

by Ross Law

Source: pharmaceutical-technology.com

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach